Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study

Orphanet Journal of Rare Diseases

Anna Wijatyk¹  Rick Martin¹  Peter Chang¹  Victoria Castaneda⁴  Yeong-Hau H Lien²  Gregory M Pastores⁵  Raphael Schiffmann³ 

[1] Shire, Lexington, MA, USA;Arizona Kidney Disease and Hypertension Center, Tucson, AZ, USA;Institute of Metabolic Disease, Baylor Research Institute, 3812 Elm Street, Dallas 75226, TX, USA;Renown Children’s Hospital, Reno, NV, USA;Current affiliation: Department of Medicine/National Centre for Inherited Metabolic Disorders, Mater Misericordiae University Hospital, Dublin, Ireland

关键词: Estimated glomerular filtration rate;    Heart rate variability;    Safety and tolerability;    Lysosomal storage disorders;    Enzyme replacement therapy;   

Others  :  1149376
DOI  :  10.1186/s13023-014-0169-6

 received in 2014-07-07, accepted in 2014-10-27,  发布年份 2014

【 摘 要 】

Background

Signs and symptoms of the X-linked disorder, Fabry disease (FD), can occur early during childhood with heterogeneous clinical manifestations including potential cardiac and renal dysfunction. Several studies support the efficacy of the enzyme replacement therapy (ERT) agalsidase alfa, in adults with FD, though published data on the long-term safety and efficacy of agalsidase alfa in children are limited. As early treatment with ERT has the potential to reduce complications arising from disease progression, children in particular could benefit. The objective of this study was to evaluate the safety and efficacy of long-term agalsidase alfa ERT in children with FD.

Methods

TKT029 was a 6.5-year open-label, multicenter, extension study of children who completed TKT023 (26-week, open-label, every-other-week, intravenous 0.2 mg/kg agalsidase alfa). TKT029 was divided into two phases (before and after an agalsidase alfa manufacturing process change); only patients who participated in both phases were included in the analysis. Primary endpoints included safety, tolerability, and heart rate variability (HRV). Additional efficacy parameters included left ventricular mass index (LVMI), estimated glomerular filtration rate (eGFR), and plasma/urine globotriaosylceramide (Gb₃).

Results

Eleven patients participated (phase 1 baseline median [range] age: 10.8 [8.6–17.3] years; 10 [90.9%] males). During TKT029 (6.5 years), all patients experienced ≥1 treatment-emergent adverse event (AE); eight patients had ≥1 possibly/probably drug-related AE. Six patients experienced infusion-related AEs, but none discontinued due to AEs. Eight serious AEs arose (two patients); none were deemed drug-related. No deaths occurred. Three patients developed anti-agalsidase alfa antibodies, with IgG antibodies in one patient that were agalsidase alfa neutralizing, but without apparent clinical impact. Renal (eGFR) endpoints remained generally in normal range. Cardiac endpoints remained stable within normal range for LVMI and a trend towards improved HRV, although some patients experienced a reduction in heart rate. Plasma and urinary Gb₃ reductions were maintained.

Conclusions

TKT029 represents the longest assessment of ERT in children with FD in a clinical trial setting. Overall, agalsidase alfa was well tolerated and demonstrated a stabilizing clinical effect. Agalsidase alfa may be a useful clinical therapeutic option for long-term treatment initiated during childhood in patients with FD.

Trial registration

http://ClinicalTrials.gov identifier NCT00084084 webcite.

【 授权许可】

   
2014 Schiffmann et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L: Enzymatic defect in Fabry’s disease. Ceramidetrihexosidase deficiency. N Engl J Med 1967, 276:1163-1167.
• [2]Ramaswami U, Parini R, Pintos-Morell G: Natural history and effects of enzyme replacement therapy in children and adolescents with Fabry disease. In Fabry Disease: Perspectives from 5 Years of FOS. Edited by Mehta A, Beck M, Sunder-Plassmann G. Oxford Pharma Genesis, Oxford; 2006.
• [3]Schiffmann R, Martin RA, Reimschisel T, Johnson K, Castaneda V, Lien YH, Pastores GM, Kampmann C, Ries M, Clarke JT: Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease. J Pediatr 2010, 156:832-837. 837 e831
• [4]Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO: Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001, 285:2743-2749.
• [5]Kampmann C, Wiethoff CM, Whybra C, Baehner FA, Mengel E, Beck M: Cardiac manifestations of Anderson-Fabry disease in children and adolescents. Acta Paediatr 2008, 97:463-469.
• [6]Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N: Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986, 57:450-458.
• [7]Counahan R, Chantler C, Ghazali S, Kirkwood B, Rose F, Barratt TM: Estimation of glomerular filtration rate from plasma creatinine concentration in children. Arch Dis Child 1976, 51:875-878.
• [8]Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F: Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006, 145:247-254.
• [9]Schiffmann R, Murray GJ, Treco D, Daniel P, Sellos-Moura M, Myers M, Quirk JM, Zirzow GC, Borowski M, Loveday K, Anderson T, Gillespie F, Oliver KL, Jeffries NO, Doo E, Liang TJ, Kreps C, Gunter K, Frei K, Crutchfield K, Selden RF, Brady RO: Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci U S A 2000, 97:365-370.
• [10]Cleeland CS, Ryan KM: Pain assessment: global use of the brief pain inventory. Ann Acad Med Singapore 1994, 23:129-138.
• [11]Feeny D, Furlong W, Torrance GW, Goldsmith CH, Zhu Z, DePauw S, Denton M, Boyle M: Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Med Care 2002, 40:113-128.
• [12]Torrance GW, Feeny DH, Furlong WJ, Barr RD, Zhang Y, Wang Q: Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. Med Care 1996, 34:702-722.
• [13][https://www.healthactchq.com/chq.php] webcite CHQ: Child Health Questionnaire™, the HealthActCHQ website. []
• [14]Silvetti MS, Drago F, Ragonese P: Heart rate variability in healthy children and adolescents is partially related to age and gender. Int J Cardiol 2001, 81:169-174.
• [15]Lobo T, Morgan J, Bjorksten A, Nicholls K, Grigg L, Centra E, Becker G: Cardiovascular testing in Fabry disease: exercise capacity reduction, chronotropic incompetence and improved anaerobic threshold after enzyme replacement. Intern Med J 2008, 38:407-414.
• [16]Shah JS, Hughes DA, Sachdev B, Tome M, Ward D, Lee P, Mehta AB, Elliott PM: Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol 2005, 96:842-846.
• [17]Kampmann C, Linhart A, Baehner F, Palecek T, Wiethoff CM, Miebach E, Whybra C, Gal A, Bultas J, Beck M: Onset and progression of the Anderson-Fabry disease related cardiomyopathy. Int J Cardiol 2008, 130:367-373.
• [18]Schiffmann R, Warnock DG, Banikazemi M, Bultas J, Linthorst GE, Packman S, Sorensen SA, Wilcox WR, Desnick RJ: Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 2009, 24:2102-2111.
• [19]Rombach SM, Aerts JM, Poorthuis BJ, Groener JE, Donker-Koopman W, Hendriks E, Mirzaian M, Kuiper S, Wijburg FA, Hollak CE, Linthorst GE: Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso) Gb3reduction and treatment outcome.PLoS One 2012, 7:e47805.